Acelrx Pharmaceuticals Stock Beta
| ACRXDelisted Stock | USD 1.01 0.01 1.00% |
AcelRx Pharmaceuticals fundamentals help investors to digest information that contributes to AcelRx Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of AcelRx Stock. The fundamental analysis module provides a way to measure AcelRx Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AcelRx Pharmaceuticals stock.
AcelRx |
AcelRx Pharmaceuticals Company Beta Analysis
AcelRx Pharmaceuticals' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current AcelRx Pharmaceuticals Beta | 0.52 |
Most of AcelRx Pharmaceuticals' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AcelRx Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, AcelRx Pharmaceuticals has a Beta of 0.517. This is 39.88% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
AcelRx Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AcelRx Pharmaceuticals' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AcelRx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing AcelRx Pharmaceuticals by comparing valuation metrics of similar companies.AcelRx Pharmaceuticals is currently under evaluation in beta category among its peers.
As returns on the market increase, AcelRx Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding AcelRx Pharmaceuticals is expected to be smaller as well.
AcelRx Fundamentals
| Return On Equity | -0.51 | |||
| Return On Asset | -0.32 | |||
| Operating Margin | (28.28) % | |||
| Current Valuation | 3.25 M | |||
| Shares Outstanding | 16.95 M | |||
| Shares Owned By Insiders | 2.63 % | |||
| Shares Owned By Institutions | 38.88 % | |||
| Number Of Shares Shorted | 508.11 K | |||
| Price To Earning | 0.39 X | |||
| Price To Book | 0.74 X | |||
| Price To Sales | 36.65 X | |||
| Revenue | 1.77 M | |||
| Gross Profit | (3.34 M) | |||
| EBITDA | (30.18 M) | |||
| Net Income | 47.76 M | |||
| Cash And Equivalents | 22.92 M | |||
| Cash Per Share | 3.11 X | |||
| Total Debt | 10.42 M | |||
| Debt To Equity | 0.43 % | |||
| Current Ratio | 1.81 X | |||
| Book Value Per Share | 1.08 X | |||
| Cash Flow From Operations | (28.33 M) | |||
| Short Ratio | 4.56 X | |||
| Earnings Per Share | (2.75) X | |||
| Target Price | 4.63 | |||
| Number Of Employees | 19 | |||
| Beta | 0.52 | |||
| Market Capitalization | 13.56 M | |||
| Total Asset | 47.49 M | |||
| Retained Earnings | (425.83 M) | |||
| Working Capital | 10.8 M | |||
| Current Asset | 118.95 M | |||
| Current Liabilities | 12.78 M | |||
| Z Score | -13.56 | |||
| Net Asset | 47.49 M |
About AcelRx Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AcelRx Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AcelRx Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AcelRx Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in AcelRx Stock
If you are still planning to invest in AcelRx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AcelRx Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |